The Role of Alendronate in Preventing New Vertebral Compression Fractures In Severe Osteoporotic Patients After Percutaneous Vertebral Augmentation: A Perspective Cohort Study

The Role of Alendronate in Preventing New Vertebral Compression Fractures In Severe OsteoporoticPatients After Percutaneous Vertebral Augmentation: A Perspective Cohort Study

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNRC-09000478

Enrollment

Unknown

Registered

2009-07-06

Start date

2005-01-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Group A:Alendronate 70mg orally taken once a week+Cacium and vitamin D supplement

Group B:Cacium and vitamin D supplement

Eligibility

Sex/Gender

All

Age

45 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Male and female aged 45 years and older; 2. Patients with osteoporotic vertebral compression fractures undergone vertebral augmentation procedures (vertebroplasty or kyphoplasty); 3. Signed informed consent.

Exclusion criteria

Exclusion criteria: Patients with traumatic vertebral compression fractures undergone vertebral augmentation procedures (vertebroplasty or kyphoplasty).

Design outcomes

Primary

Measure	Time frame
Rate of new adjacent VCFs;Rate of new VCF;	—

Secondary

Measure	Time frame
Score of visual analogue scale for pain;Score of locomotor activity scale;Score of Taking analgesics scale;	—

Countries

China

Contacts

Public ContactDecai Chen

cdecai@yahoo.com.cn+86 028 85422360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026